Evidence map›Paper›PMID 36481221›Full record

ArticleOphthalmology2023

Reticular Pseudodrusen Status, ARMS2/HTRA1 Genotype, and Geographic Atrophy Enlargement: Age-Related Eye Disease Study 2 Report 32.

Elvira Agrón, Amitha Domalpally, Catherine A Cukras, Traci E Clemons, Qingyu Chen, Anand Swaroop, Zhiyong Lu, Emily Y Chew, Tiarnan D L Keenan, AREDS and AREDS2 Research Groups

Open access · greenAbstract read
In one paragraph

Article in Ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Bidirectional Retro mode differential imaging improves drusen boundary depiction in early and intermediate AMD: a pilot study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Elvira AgrónDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Amitha DomalpallyDepartment of Ophthalmology and Visual Sciences, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin.
Catherine A CukrasDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Traci E ClemonsThe Emmes Company LLC, Rockville, Maryland.
Qingyu ChenNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland.
Anand SwaroopNeurobiology-Neurodegeneration & Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Zhiyong LuNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland.
Emily Y ChewDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: echew@nei.nih.gov.
Tiarnan D L KeenanDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: tiarnan.keenan@nih.gov.
AREDS and AREDS2 Research Groups
National Institutes of Health · USEmmes (United States) · USUniversity of Wisconsin–Madison · US

Funding

Mechanisms, modeling and therapies of retinal and macular neurodegenerationZIAEY000546 · NEI · NATIONAL EYE INSTITUTE · PI SWAROOP, ANAND · 2015 to 2025
$36.3M
THE LUTEIN/ZEAXANTHIN AND OMEGA-3 SUPPLEMENT TRIAL--A MULTI CENTER, RANDOMIZED TN01EY50007 · NEI · THE EMMES COMPANY, LLC · PI CLEMONS, TRACI · 2007 to 2011
$23.3M
Machine learning for medical imaging: automated disease diagnosis and prognosisZIALM010021 · NLM · NATIONAL LIBRARY OF MEDICINE · PI LU, ZHIYONG · 2022 to 2025
$4.1M
AGE RELATED EYE DISEASE STUDY - COORDINATING CENTERN01EY002127 · NEI · EMMES CORPORATION · PI EDERERI, FRED · 1990 to 2000
$1.7M
Novel Bioinformatics Tools for Gene Regulatory Network InferenceK99LM010824 · NLM · WASHINGTON UNIVERSITY · PI CHANG, LI-WEI · 2010 to 2011
$180k
Intramural NIH HHS Z99 EY999999Intramural NIH HHS ZIA EY000546NEI NIH HHS N01 EY002127NEI NIH HHS N01EY50007NLM NIH HHS K99 LM010824
6 · The paper itself

Abstract

purposeTo determine whether reticular pseudodrusen (RPD) status, ARMS2/HTRA1 genotype, or both are associated with altered geographic atrophy (GA) enlargement rate and to analyze potential mediation of genetic effects by RPD status.

designPost hoc analysis of an Age-Related Eye Disease Study 2 cohort.

participantsEyes with GA: n = 771 from 563 participants.

methodsGeographic atrophy area was measured from fundus photographs at annual visits. Reticular pseudodrusen presence was graded from fundus autofluorescence images. Mixed-model regression of square root of GA area was performed by RPD status, ARMS2 genotype, or both.

main outcome measuresChange in square root of GA area.

resultsGeographic atrophy enlargement was significantly faster in eyes with RPD (P < 0.0001): 0.379 mm/year (95% confidence interval [CI], 0.329-0.430 mm/year) versus 0.273 mm/year (95% CI, 0.256-0.289 mm/year). Enlargement was also significantly faster in individuals carrying ARMS2 risk alleles (P < 0.0001): 0.224 mm/year (95% CI, 0.198-0.250 mm/year), 0.287 mm/year (95% CI, 0.263-0.310 mm/year), and 0.307 mm/year (95% CI, 0.273-0.341 mm/year) for 0, 1, and 2, respectively. In mediation analysis, the direct effect of ARMS2 genotype was 0.074 mm/year (95% CI, 0.009-0.139 mm/year), whereas the indirect effect of ARMS2 genotype via RPD status was 0.002 mm/year (95% CI, -0.006 to 0.009 mm/year). In eyes with incident GA, RPD presence was not associated with an altered likelihood of central involvement (P = 0.29) or multifocality (P = 0.16) at incidence. In eyes with incident noncentral GA, RPD presence was associated with faster GA progression to the central macula (P = 0.009): 157 μm/year (95% CI, 126-188 μm/year) versus 111 μm/year (95% CI, 97-125 μm/year). Similar findings were observed in the Age-Related Eye Disease Study.

conclusionsGeographic atrophy enlargement is faster in eyes with RPD and in individuals carrying ARMS2/HTRA1 risk alleles. However, RPD status does not mediate the association between ARMS2/HTRA1 genotype and faster enlargement. Reticular pseudodrusen presence and ARMS2/HTRA1 genotype are relatively independent risk factors, operating by distinct mechanisms. Reticular pseudodrusen presence does not predict central involvement or multifocality at GA incidence but is associated with faster progression toward the central macula. Reticular pseudodrusen status should be considered for improved predictions of enlargement rate. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

Indexed as

Geographic AtrophyRetinal DrusenAllelesFluorescein AngiographyGenotypeHigh-Temperature Requirement A Serine Peptidase 1HumansProteinsRisk FactorsARMS2 protein, humanHigh-Temperature Requirement A Serine Peptidase 1HTRA1 protein, humanProteinsAge-Related Eye Disease Study 2Age-related macular degenerationGeographic atrophyReticular pseudodrusenSubretinal drusenoid deposit

Identifiers

PMID36481221
PMCPMC10121754
OpenAlexW4310946147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.